Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2

Han Song Ju, Hyun Kim Seung, Dae Ho Cho, Il Kwon Lee, Hyeoung Joon Kim, Tae Sung Kim

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The acquired drug resistance as well as extramedullary tissue infiltration of leukemic cells is a major obstacle in leukemia treatment. Excessive egress of leukemia cell blasts results in invasion into various organs or tissues, which is facilitated by the catalytic activities of matrix metalloproteinases (MMPs). However, the migration of chemoresistant leukemia cells remains unclear. Here, we generated drug-resistant variants of the human acute myeloid leukemia cell line (AML-2/WT) by stepwise exposure to anticancer drugs and evaluated the level of MMP-2 in the drug-resistant variants, along with their invasiveness. Each of the drug-resistant cell variants demonstrated predominant increases in the expression and gelatinolytic activity of MMP-2 as well as in invasiveness, which were significantly suppressed by both a MMP-2 inhibitor and a blocking antibody. Knockdown experiments using MMP-2 short hairpin RNA also indicated that its upregulation was strongly associated with the cells' increased invasive properties. Importantly, elevated levels of MMP-2 activity and invasiveness were observed in ex vivo mononuclear cell of bone marrow from patients with poor responses to chemotherapy. These findings suggest that advanced malignancy due to acquired drug resistance is responsible for the progressive invasiveness of leukemia cells via MMP-2.

Original languageEnglish
Pages (from-to)1074-1081
Number of pages8
JournalInternational Journal of Cancer
Volume125
Issue number5
DOIs
Publication statusPublished - 2009 Sep 1

Fingerprint

Matrix Metalloproteinase 2
Myeloid Cells
Acute Myeloid Leukemia
Leukemia
Pharmaceutical Preparations
Drug Resistance
Leukemic Infiltration
Blocking Antibodies
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Bone Marrow Cells
Small Interfering RNA
Up-Regulation
Drug Therapy
Cell Line
Neoplasms

Keywords

  • Acute myeloid leukemia
  • Drug resistance
  • Invasion
  • Matrix metalloproteinase-2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2. / Ju, Han Song; Seung, Hyun Kim; Cho, Dae Ho; Lee, Il Kwon; Kim, Hyeoung Joon; Kim, Tae Sung.

In: International Journal of Cancer, Vol. 125, No. 5, 01.09.2009, p. 1074-1081.

Research output: Contribution to journalArticle

@article{8d90c5dd7e104b4984c4cc7dfc34780c,
title = "Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2",
abstract = "The acquired drug resistance as well as extramedullary tissue infiltration of leukemic cells is a major obstacle in leukemia treatment. Excessive egress of leukemia cell blasts results in invasion into various organs or tissues, which is facilitated by the catalytic activities of matrix metalloproteinases (MMPs). However, the migration of chemoresistant leukemia cells remains unclear. Here, we generated drug-resistant variants of the human acute myeloid leukemia cell line (AML-2/WT) by stepwise exposure to anticancer drugs and evaluated the level of MMP-2 in the drug-resistant variants, along with their invasiveness. Each of the drug-resistant cell variants demonstrated predominant increases in the expression and gelatinolytic activity of MMP-2 as well as in invasiveness, which were significantly suppressed by both a MMP-2 inhibitor and a blocking antibody. Knockdown experiments using MMP-2 short hairpin RNA also indicated that its upregulation was strongly associated with the cells' increased invasive properties. Importantly, elevated levels of MMP-2 activity and invasiveness were observed in ex vivo mononuclear cell of bone marrow from patients with poor responses to chemotherapy. These findings suggest that advanced malignancy due to acquired drug resistance is responsible for the progressive invasiveness of leukemia cells via MMP-2.",
keywords = "Acute myeloid leukemia, Drug resistance, Invasion, Matrix metalloproteinase-2",
author = "Ju, {Han Song} and Seung, {Hyun Kim} and Cho, {Dae Ho} and Lee, {Il Kwon} and Kim, {Hyeoung Joon} and Kim, {Tae Sung}",
year = "2009",
month = "9",
day = "1",
doi = "10.1002/ijc.24386",
language = "English",
volume = "125",
pages = "1074--1081",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2

AU - Ju, Han Song

AU - Seung, Hyun Kim

AU - Cho, Dae Ho

AU - Lee, Il Kwon

AU - Kim, Hyeoung Joon

AU - Kim, Tae Sung

PY - 2009/9/1

Y1 - 2009/9/1

N2 - The acquired drug resistance as well as extramedullary tissue infiltration of leukemic cells is a major obstacle in leukemia treatment. Excessive egress of leukemia cell blasts results in invasion into various organs or tissues, which is facilitated by the catalytic activities of matrix metalloproteinases (MMPs). However, the migration of chemoresistant leukemia cells remains unclear. Here, we generated drug-resistant variants of the human acute myeloid leukemia cell line (AML-2/WT) by stepwise exposure to anticancer drugs and evaluated the level of MMP-2 in the drug-resistant variants, along with their invasiveness. Each of the drug-resistant cell variants demonstrated predominant increases in the expression and gelatinolytic activity of MMP-2 as well as in invasiveness, which were significantly suppressed by both a MMP-2 inhibitor and a blocking antibody. Knockdown experiments using MMP-2 short hairpin RNA also indicated that its upregulation was strongly associated with the cells' increased invasive properties. Importantly, elevated levels of MMP-2 activity and invasiveness were observed in ex vivo mononuclear cell of bone marrow from patients with poor responses to chemotherapy. These findings suggest that advanced malignancy due to acquired drug resistance is responsible for the progressive invasiveness of leukemia cells via MMP-2.

AB - The acquired drug resistance as well as extramedullary tissue infiltration of leukemic cells is a major obstacle in leukemia treatment. Excessive egress of leukemia cell blasts results in invasion into various organs or tissues, which is facilitated by the catalytic activities of matrix metalloproteinases (MMPs). However, the migration of chemoresistant leukemia cells remains unclear. Here, we generated drug-resistant variants of the human acute myeloid leukemia cell line (AML-2/WT) by stepwise exposure to anticancer drugs and evaluated the level of MMP-2 in the drug-resistant variants, along with their invasiveness. Each of the drug-resistant cell variants demonstrated predominant increases in the expression and gelatinolytic activity of MMP-2 as well as in invasiveness, which were significantly suppressed by both a MMP-2 inhibitor and a blocking antibody. Knockdown experiments using MMP-2 short hairpin RNA also indicated that its upregulation was strongly associated with the cells' increased invasive properties. Importantly, elevated levels of MMP-2 activity and invasiveness were observed in ex vivo mononuclear cell of bone marrow from patients with poor responses to chemotherapy. These findings suggest that advanced malignancy due to acquired drug resistance is responsible for the progressive invasiveness of leukemia cells via MMP-2.

KW - Acute myeloid leukemia

KW - Drug resistance

KW - Invasion

KW - Matrix metalloproteinase-2

UR - http://www.scopus.com/inward/record.url?scp=67650034623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650034623&partnerID=8YFLogxK

U2 - 10.1002/ijc.24386

DO - 10.1002/ijc.24386

M3 - Article

C2 - 19449375

AN - SCOPUS:67650034623

VL - 125

SP - 1074

EP - 1081

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -